Form 4: Nelson Obus Reports Acquisition of 30,000 Lifecore Biomedical Shares

Director Nelson Obus reports acquiring 30,000 shares of Lifecore Biomedical common stock on July 8, 2024, increasing his direct holdings to 118,687 shares.

Summary

• On July 8, 2024, Nelson Obus, a director of Lifecore Biomedical, Inc., acquired 30,000 shares of common stock.
• The acquisition was made directly.
• Following the transaction, Obus directly owns 118,687 shares of Lifecore Biomedical.
• The acquired shares are in the form of restricted stock units that convert into common stock on a 1-for-1 basis.
• The restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director. The acquisition itself could be seen as a positive signal, but the document is purely informational.

Positives

• A director's increased stake in the company may signal confidence in its future prospects.

Future Outlook

The restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• The increased holding by a director could be viewed positively by shareholders.

Key Dates